We are happy to announce that we have received approval for a Baekeland mandate to kick off a new innovation initiative at our facilities.

This project will focus on the development of innovative LC-MS tools for the detailed characterization of biopharmaceutical products with the final aim of broadening our portfolio and further strengthen our leading position in the field.

Protein biopharmaceuticals such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) are today the growth domains for the pharmaceutical industry. Together with a huge therapeutic potential, these molecules come with a complexity that drives state-of-the-art chromatography and mass spectrometry to its limits.

This project will be led by our colleague Liesa Verscheure as part of her PhD track.
We wish Liesa all the best with her newest challenge!